Immunome Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company that discovers and develops antibody-drug conjugates and other targeted cancer therapies. The company generates no product revenue, funding operations through equity issuances, including public offerings, at-the-market programs, and stock issued under licensing and asset purchase agreements with partners such as Bristol Myers Squibb and Zentalis. Immunome's pipeline as of the 10-K filed March 3, 2026 includes six named programs: IM-1617, an ADC targeting a receptor tyrosine kinase expressed across colorectal cancer, non-small cell lung cancer, breast cancer, and ovarian cancer; IM-1340, an ADC for neuroendocrine tumors, lung, and prostate tumors; and IM-1335, an optimized ADC for solid tumor indications. All manufacturing is outsourced to third-party contract manufacturers. The company holds a license from Purdue Research Foundation and conducts IND-enabling studies through external vendors. Immunome carries an accumulated deficit and has not achieved commercial-stage operations as of December 31, 2025.

Revenue model

No product revenue as of December 31, 2025. Capital raised through public equity offerings, at-the-market stock issuances, and common stock issued under licensing and asset purchase agreements, including arrangements with Bristol Myers Squibb and Zentalis.

Products and services

Pipeline of antibody-drug conjugates (ADCs) and targeted oncology therapies: IM-1617 (solid tumor ADC targeting a receptor tyrosine kinase; IND submission targeted for early 2026), IM-1340 (solid tumor ADC targeting neuroendocrine tumors and lung/prostate; IND submission targeted for mid-2026), and IM-1335 (solid tumor ADC). All programs are in preclinical or IND-enabling stages as of the filing date.

Customers and end markets

No commercial customers as of December 31, 2025. End markets are oncology indications including colorectal cancer, non-small cell lung cancer, breast cancer, ovarian cancer, neuroendocrine tumors, lung cancer, and prostate cancer.

Value-chain role

Drug discovery and development company operating upstream of commercialization. Relies entirely on third-party contract manufacturers for production of antibodies, linkers, payloads, ADCs, and radioligand therapy components. Clinical and preclinical activities conducted through third-party vendors under contract research agreements.

Geographic exposure

Operates in the United States. Subject to data transfer and regulatory requirements in the European Economic Area and United Kingdom in connection with clinical trial data handling.

Source: SEC 10-K, filed 2026-03-03

Industry: Pharmaceutical Preparations Peers: Dyadic International Inc PharmaCyte Biotech Inc Exagen Inc Lantern Pharma Inc Lite Strategy Inc MERRIMACK PHARMACEUTICALS INC Minerva Neurosciences Inc Sera Prognostics Inc TScan Therapeutics Inc